Heparină Sodică Panpharma

Heparină Sodică Panpharma is an injectable solution containing the anticoagulant heparin sodium. The product is supplied in a sterile liquid form for intravenous administration and is marketed in the European Union. It is a prescription‑only medication used to inhibit clot formation by enhancing antithrombin III activity, targeting thrombin and factor Xa in the coagulation cascade.

Heparină Sodică Panpharma is employed in clinical settings to prevent and treat thromboembolic conditions. It is indicated for several high‑risk situations where clot formation must be controlled.

- Prevention and treatment of deep vein thrombosis (DVT) - Prevention and treatment of pulmonary embolism (PE) - Prophylaxis of thromboembolic events during major surgery or orthopedic procedures - Management of acute coronary syndromes, including unstable angina and myocardial infarction - Use in patients requiring rapid anticoagulation during interventional cardiology procedures

Heparină Sodică Panpharma may cause a range of adverse reactions, most of which are related to its anticoagulant activity. Patients should be monitored for both common and serious events.

Common: - Minor bleeding at injection site - Nosebleeds (epistaxis) - Hematuria (blood in urine) - Gastrointestinal irritation or mild abdominal pain - Elevated liver enzymes (transient)

Serious: - Major hemorrhage (intracranial, gastrointestinal, or surgical site) - Heparin‑induced thrombocytopenia (HIT) - Allergic reactions, including anaphylaxis - Spontaneous spinal or epidural hematoma

Before initiating Heparină Sodică Panpharma, clinicians should assess individual risk factors and monitor patients closely. Specific considerations include: - Baseline complete blood count and coagulation parameters (aPTT, PT/INR) - History of bleeding disorders, recent surgery, or trauma - Renal or hepatic impairment may alter drug clearance - Pregnancy category B; use only if benefit outweighs risk - Caution in patients with uncontrolled hypertension - Avoid concurrent use with other anticoagulants unless specifically indicated

Heparină Sodică Panpharma can interact with several medications, affecting bleeding risk or anticoagulant efficacy. Interaction management is essential.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without careful monitoring - Thrombolytic agents (e.g., alteplase, streptokinase) - High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs)

Use with caution: - Antiplatelet drugs (e.g., clopidogrel, ticagrelor) - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents - Glycoprotein IIb/IIIa inhibitors - Certain antibiotics (e.g., vancomycin) that may potentiate bleeding